Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | PLA2G4B | P0C869 | 7/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | RARB | P10826 | 4/20 | 0.60 |
| ▸ | HTT | P42858 | 3/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | APEX1 | P27695 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22238893 | 1.00 | TP53 (0.66) | TP53TSHRPLA2G4BALDH1A1L3MBTL1 | |
| SCHEMBL28461372 | 1.00 | TP53 (0.66) | TP53TSHRPLA2G4BALDH1A1L3MBTL1 | |
| SCHEMBL1744967 | 1.00 | TP53 (0.66) | TP53TSHRPLA2G4BALDH1A1L3MBTL1 | |
| SCHEMBL29044815 | 1.00 | TP53 (0.66) | TP53TSHRPLA2G4BALDH1A1L3MBTL1 | |
| SCHEMBL557505 | 1.00 | TP53 (0.66) | TP53TSHRPLA2G4BALDH1A1L3MBTL1 | |
| SCHEMBL28258061 | 0.88 | ALDH1A1 (0.65) | TP53TSHRPLA2G4BALDH1A1L3MBTL1 | |
| SCHEMBL14097198 | 0.88 | TP53 (0.82) | TP53TSHRPLA2G4BALDH1A1L3MBTL1 | |
| SCHEMBL7911508 | 0.88 | TP53 (0.82) | TP53TSHRPLA2G4BALDH1A1L3MBTL1 | |
| SCHEMBL209561 | 0.88 | TP53 (0.82) | TP53TSHRPLA2G4BALDH1A1L3MBTL1 | |
| SCHEMBL2181009 | 0.88 | TP53 (0.82) | TP53TSHRPLA2G4BALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067362-B2 | Antidiabetic agents; genetic engineered polypeptide; having a side chain attached alpha -amino group of the N-terminal amino acid of the B chain via an amide bond, with free carboxylic acid group, a fatty acid; soluble at physiological pH, prolonged profile of action; hypoglycemic agents | NOVO NORDISK AS (DK) | 2011-11-29 | — | — | US | claimed |
| US-20230331803-A1 | CO-AGONISTS OF THE GLP-1 AND AMYLIN RECEPTORS | NOVO NORDISK A/S (DK) | 2023-10-19 | — | — | US | disclosed |
| CN-115298207-A | GIP/GLP1 co-agonist compounds | 伊莱利利公司 | 2022-11-04 | — | — | CN | disclosed |
| US-10822385-B2 | EGF(A) analogues with fatty acid substituents | NOVO NORDISK A/S (DK) | 2020-11-03 | — | — | US | disclosed |
| EP-2820038-B1 | GLP-1 PRODRUGS | NOVO NORDISK AS (DK) | 2020-06-17 | — | — | EP | disclosed |
| US-20190016768-A1 | EGF(A) ANALOGUES WITH FATTY ACID SUBSTITUENTS | NOVO NORDISK A/S (DK) | 2019-01-17 | — | — | US | disclosed |
| US-20170182124-A1 | FGF21 Derivatives and Uses Thereof | NOVO NORDISK A/S (DK) | 2017-06-29 | — | — | US | disclosed |
| US-RE46170-E1 | Insulin derivatives | NOVO NORDISK A/S (DK) | 2016-10-04 | — | — | US | disclosed |
| EP-2256130-B1 | Novel insulin derivatives | NOVO NORDISK AS (DK) | 2013-09-25 | — | — | EP | disclosed |
| US-8476228-B2 | Insulin derivatives | NOVO NORDISK A/S (DK) | 2013-07-02 | — | — | US | disclosed |
| EP-1846446-B1 | INSULIN DERIVATIVES | NOVO NORDISK AS (DK) | 2013-06-26 | — | — | EP | disclosed |
| US-20120035104-A1 | Insulin derivatives | NOVO NORDISK A/S (DK) | 2012-02-09 | — | — | US | disclosed |
| US-8067362-B2 | Antidiabetic agents; genetic engineered polypeptide; having a side chain attached alpha -amino group of the N-terminal amino acid of the B chain via an amide bond, with free carboxylic acid group, a fatty acid; soluble at physiological pH, prolonged profile of action; hypoglycemic agents | NOVO NORDISK AS (DK) | 2011-11-29 | — | — | US | disclosed |
| EP-2256130-A1 | Novel insulin derivatives | Novo Nordisk A/S (DK) | 2010-12-01 | — | — | EP | disclosed |
| US-20080076705-A1 | Insulin Derivatives | NOVO NORDISK A/S (DK) | 2008-03-27 | — | — | US | disclosed |
| EP-1846446-A1 | INSULIN DERIVATIVES | NOVO NORDISK A/S (DK) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006082204-A1 | INSULIN DERIVATIVES | NOVO NORDISK A/S (DK) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170182124-A1 | FGF21 Derivatives and Uses Thereof | FGF2, FGFR1, FGF1 | TP53 2284/4885TSHR 426/4885PLA2G4B 3833/4885 |
| US-20120035104-A1 | Insulin derivatives | IAPP, INSR, GPR119 | TP53 4688/4885TSHR 677/4885PLA2G4B 1170/4885 |
| US-20190016768-A1 | EGF(A) ANALOGUES WITH FATTY ACID SUBSTITUENTS | EGFR, LDLR, FFAR2 | TP53 2924/4885TSHR 265/4885PLA2G4B 788/4885 |
| US-20230331803-A1 | CO-AGONISTS OF THE GLP-1 AND AMYLIN RECEPTORS | GLP1R, GIPR, GCGR | TP53 4580/4885TSHR 202/4885PLA2G4B 3608/4885 |
| US-20080076705-A1 | Insulin Derivatives | IAPP, INSR, GPR119 | TP53 4678/4885TSHR 597/4885PLA2G4B 1242/4885 |
| US-10822385-B2 | EGF(A) analogues with fatty acid substituents | EGFR, LDLR, FFAR2 | TP53 2924/4885TSHR 265/4885PLA2G4B 788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.